United Therapeutics 주식 (NASDAQ: UTHR)

에 대한 최신 뉴스 United Therapeutics (NASDAQ:UTHR) 주식

United Therapeutics

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Equities

News

Markets

ABNB

AVGO

NVDA

PLTR

TSLA

UTHR

VRTX

전설적인 수학자이자 전 국가안보국(NSA) 암호 해독자인 짐 사이먼스(Jim Simons)가 설립한 헤지펀드인 르네상스 테크놀로지스(Renaissance Technologies)는 최근 8월 9일 미국 증권거래위원회(SEC)에 제출한 13F의 최신 주요 주식 보유 현황을 공시했다.

NSA 암호해독 전문가 짐 사이먼스의 헤지펀드 르네상스의 보유 주식 - 노보 노디스크 등

Large Cap

Movers

Trading Ideas

AMZN

LINE

MBLY

RIVN

SIRI

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 텐센트 뮤직 엔터테인먼트 그룹(NYSE:TME)이 2분기 매출 부진을 보고한 후 주가는 18.18% 하락했다. 몇몇 분석가들은 주식의 목표 주가를 낮췄다. 

리비안과 치폴레는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 11일-8월 17일)

United Therapeutics Corporation - Common Stock

United Therapeutics Corp

In the current market session, United Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) stock price is at $350.07, after a 0.68% decrease. However, over the past month, the company's stock went up by 0.02%, and in the past year, by 49.39%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1727988397_0.png" alt="Past Year Chart" />

<h3>United Therapeutics P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 61.21 in the Biotechnology industry, United Therapeutics Inc. has a lower P/E ratio of 16.2. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1727988397_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into United Therapeutics Inc's Price Over Earnings

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) has outperformed the market over the past 5 years by 20.7% on an annualized basis producing an average annual return of 34.64%. Currently, United Therapeutics has a market capitalization of $15.82 billion. 
Buying $1000 In UTHR: If an investor had bought $1000 of UTHR stock 5 years ago, it would be worth $4,364.49 today based on a price of $355.59 for UTHR at the time of writing.
<h3>United Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727186420_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today

Data from the&nbsp;BREEZE&nbsp;open-label extension study of Tyvaso DPI&nbsp;detail its long-term outcomes and dosing in patients with pulmonary arterial hypertension.

United Therapeutics Plans Five Presentations And One Poster Across Its Commercial And Development Portfolio At The CHEST 2024 Annual Meeting

Analysts' ratings for United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated United Therapeutics and provided 12-month price targets. The average target is $389.78, accompanied by a high estimate of $575.00 and a low estimate of $280.00. This current average reflects an increase of 18.99% from the previous average price target of $327.56. 
<img src="https://www.benzinga.com/files/images/story/2024/1727110819_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of United Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eun Yang</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$432.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$575.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$280.00</td>
<td>$303.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Thome</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$321.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to United Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of United Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of United Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Delving into United Therapeutics's Background</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>Financial Insights: United Therapeutics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, United Therapeutics showcased positive performance, achieving a revenue growth rate of 19.85% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.9% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): United Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Key Takeaways From United Therapeutics Analyst Ratings

Jefferies analyst Eun Yang maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and raises the price target from $315 to $432.

Price Target

Jefferies Maintains Buy on United Therapeutics, Raises Price Target to $432

Foghorn Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fhtx#NASDAQ">FHTX</a>) shares rallied 9.5% in the last trading session to close at $9.72. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock&#39;s 43.2% gain over the past four weeks.
Last month, the company announced robust financial results for the second quarter of 2024. Studies on the company&#39;s pipeline candidates for treating various oncology indications are progressing well. This might have been driving the share price rally.
This company is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of -20.6%. Revenues are expected to be $7.01 million, down 59.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Foghorn Therapeutics, the consensus EPS estimate for the quarter has been revised 7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn&#39;t usually translate into price appreciation. So, make sure to keep an eye on FHTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy).
Foghorn Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, United Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uthr#NASDAQ">UTHR</a>), closed the last trading session 0.6% lower at $339.12. Over the past month, UTHR has returned 5.6%.
For United Therapeutics, the consensus EPS estimate for the upcoming report has changed +0.1% over the past month to $6.33. This represents a change of +17.7% from what the company reported a year ago. United Therapeutics currently has a Zacks Rank of #3 (Hold).
<a href="https://www.zacks.com/stock/news/2336199/strength-seen-in-foghorn-therapeutics-fhtx-can-its-9-5-jump-turn-into-more-strength?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_5%-2336199">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Small Cap

General

FHTX

Strength Seen in Foghorn Therapeutics: Can Its 9.5% Jump Turn into More Strength?

Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the District of New Jersey (District Court) has found that the interference by United Therapeutics Corporation (United Therapeutics) with the launch of generic Treprostinil Injection caused losses in excess of $137M. Treprostinil Injection is manufactured by Sandoz Inc. (Sandoz) and was launched as the first-to-file, fully-substitutable generic treprostinil for parenteral administration in March 2019. Liquidia PAH, LLC (formerly known as RareGen), a wholly owned subsidiary of Liquidia (Liquidia PAH), partnered with Sandoz in August 2018 on an exclusive basis to market and commercialize Treprostinil Injection.

Legal

LQDA

Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M

Federal regulators are grappling with a significant backlog of factory inspections for drug manufacturing, with many facilities not reviewed since before the pandemic.
An analysis by The Associated Press of FDA data revealed that approximately 42% of the 4,700 registered plants have not undergone FDA surveillance inspections since 2019.
These facilities produce crucial medicines such as antibiotics, blood thinners, and cancer therapies, raising concerns over potential contamination and quality issues.
An AP analysis reveals that approximately 2,000 pharmaceutical manufacturers have not undergone FDA surveillance inspections since before the pandemic. This oversight raises potential contamination risks and other safety issues in medications.
A scholar from Duke University expressed concerns about generic drugmakers reducing costs at the expense of quality, which remains unchecked without proper inspections in an ABC News report.
Tainted medications, like the 2022 incident involving antibiotic-resistant bacteria in eyedrops from an Indian factory, underscore the risks of insufficient oversight.
These factories, particularly in India and China, are critical suppliers of low-cost prescription ingredients in the U.S.
Despite the challenges, FDA Associate Commissioner Michael Rogers <a target="_blank" href="https://abcnews.go.com/Health/wireStory/2000-drug-manufacturing-plants-overdue-fda-inspections-after-113414456" rel="noreferrer noopener">asserted</a> that the FDA is the world&#8217;s most stringent drug regulator. However, he acknowledged that inspection rates are still nearly 40% lower than pre-COVID levels, with no set timeline for clearing the backlog.
The situation is exacerbated by staffing challenges, with many experienced inspectors leaving for more flexible job opportunities.
Internationally, the FDA has been using video and online tools for preliminary assessments, but these do not substitute for physical inspections.
The Government Accountability Office has consistently marked this area as high-risk, signaling that more proactive measures are necessary. In the meantime, the FDA focuses on a risk-based approach to prioritize inspections that pose the greatest public health risk.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40750262/mpox-vaccines-challenges-persist-as-congo-receives-first-batch-of-doses-almost-2-years-after-it-d" target="_blank" rel="noreferrer noopener">Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic</a>.</li>
</ul>
Photo via Shutterstock

Government

Regulations

Health Care

BMRN

FDA Battles Backlog of Drug Factory Inspections Since COVID-19

WIIM

United Therapeutics shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $400 to $572.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Oppenheimer raised the price target for United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from $400 to $575. Oppenheimer analyst Hartaj Singh maintained an Outperform rating. United Therapeutics shares gained 0.7% to close at $349.23 on Tuesday. <a href="https://www.benzinga.com/quote/UTHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho lowered the price target for BILL Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) from $60 to $52. Mizuho analyst Siti Panigrahi maintained a Neutral rating. BILL Holdings shares gained 7.5% to close at $53.48 on Tuesday. <a href="https://www.benzinga.com/quote/BILL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Craig-Hallum raised Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) price target from $80 to $85. Craig-Hallum analyst Richard Shannon maintained a Buy rating. Ambarella shares gained 3.2% to close at $52.79 on Tuesday. <a href="https://www.benzinga.com/quote/AMBA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group cut the price target for Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) from $190 to $170. Evercore ISI Group analyst Stephen Richardson maintained an Outperform rating. Albemarle shares gained 0.04% to close at $88.98 on Tuesday. <a href="https://www.benzinga.com/quote/ALB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital raised Cognizant Technology Solutions Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) price target from $81 to $82. RBC Capital analyst Daniel Perlin maintained a Sector Perform rating. Cognizant Technology shares rose 0.4% to close at $77.15 on Tuesday.<a href="https://www.benzinga.com/quote/CTSH/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>B of A Securities raised Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) price target from $18 to $20. B of A Securities analyst Lorraine Hutchinson maintained an Underperform rating. Nordstrom shares fell 2.5% to close at $21.14 on Tuesday. <a href="https://www.benzinga.com/quote/JWN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird increased the price target for The Toro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) from $100 to $102. Baird analyst Timothy Wojs maintained a Neutral rating. Toro Company shares gained 0.2% to close at $90.60 on Tuesday. <a href="https://www.benzinga.com/quote/TTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein boosted Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) price target from $68 to $70. Bernstein analyst Peter Weed maintained a Market Perform rating. Twilio shares gained 2.2% to close at $61.99 on Tuesday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) price target from $552 to $448. Deutsche Bank analyst Krisztina Katai maintained a Buy rating. Ulta Beauty shares fell 1% to close at $371.35 on Tuesday. <a href="https://www.benzinga.com/quote/ULTA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup raised Delek Logistics Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKL#NYSE">DKL</a>) price target from $44 to $45. Citigroup analyst Douglas Irwin upgraded the stock from Neutral to Buy. Delek Logistics Partners shares fell 0.4% to close at $38.83 on Tuesday. <a href="https://www.benzinga.com/quote/DKL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AMBA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="513" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/28091528/image-284-1024x513.png" alt="" class="wp-image-518397" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/28091528/image-284-1024x513.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/28091528/image-284-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/28091528/image-284-768x385.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/28091528/image-284.png 1350w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Pre-Market Outlook

AMBA

BILL

CTSH

TWLO

ULTA

Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday

Oppenheimer analyst Hartaj Singh maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Outperform and raises the price target from $400 to $575.

Oppenheimer Maintains Outperform on United Therapeutics, Raises Price Target to $575

In the last three months, 8 analysts have published ratings on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $356.38, a high estimate of $400.00, and a low estimate of $280.00. Observing a 11.46% increase, the current average has risen from the previous average price target of $319.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1724173236_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive United Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$280.00</td>
<td>$303.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Thome</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$321.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$325.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of United Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Delving into United Therapeutics's Background</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>Unraveling the Financial Story of United Therapeutics</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 19.85%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 38.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): United Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA excels beyond industry benchmarks, reaching 4.21%. This signifies efficient management of assets and strong financial health.
Debt Management: United Therapeutics's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts

Wells Fargo analyst Tiago Fauth maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Overweight and raises the price target from $350 to $380.

Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $380

Editor&#8217;s Note: The headline has been revised for clarity.
Renaissance Technologies, the hedge fund founded by legendary mathematician and former National Security Agency code breaker Jim Simons, recently disclosed its <a href="https://www.benzinga.com/news/24/05/38768433/jim-simons-groundbreaking-quantitative-hedge-fund-founder-who-provided-exceptional-returns-for-inves">latest stock holdings in a 13F filing</a> with the U.S. Securities and Exchange Commission on Aug. 9. 
What Happened:&nbsp;The filing <a href="https://www.sec.gov/Archives/edgar/data/1037389/000103738924000073/xslForm13F_X02/renaissance13Fq22024_holding.xml">reveals</a> significant changes in the fund&#8217;s portfolio, reflecting the quantitative strategies that have made Renaissance one of the most successful hedge funds in history.
Leading the pack is Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), a Danish pharmaceutical giant, which accounts for 2.22% of Renaissance&#8217;s portfolio with a market value of $1.3 billion. Despite a 15.03% reduction in shares, NVO remains the fund&#8217;s top holding.
In a notable shift, Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) ranks second, comprising 1.70% of the portfolio. However, Renaissance decreased its PLTR position by 16.56%, signaling a potential reassessment of the data analytics firm&#8217;s prospects.
NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), a leader in AI and graphics processing, saw a significant increase in Renaissance&#8217;s holdings. The fund boosted its NVDA shares by 27.52%, making it the third-largest position at 1.47% of the portfolio.
Other top holdings include Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) and United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), underscoring Renaissance&#8217;s interest in the healthcare sector.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) saw a significant reduction of 33.39% in shares held, now representing 0.89% of the portfolio. Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) also experienced a substantial decrease of 23.11%, accounting for 0.87% of Renaissance&#8217;s holdings with a market value of $515.76 million.
Notably, Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) appears as a new position in the portfolio, claiming the ninth spot with 0.80% of total holdings and a market value of $472.21 million.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) completes the top 10, with Renaissance increasing its stake by 14.20%. TSLA now represents 0.69% of the portfolio, valued at $405.94 million.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/08/40436129/more-than-half-of-fortune-500-companies-flag-ai-as-a-major-risk-marking-473-5-surge-in-warnings-amid">More Than Half Of Fortune 500 Companies Flag AI As A Major Risk, Marking 473.5% Surge In Warnings Amid Growing Concerns</a>
Why It Matters: This latest 13F offers a glimpse into the investment strategies of Renaissance Technologies, now led by CEO Peter Brown following the <a href="https://www.benzinga.com/news/large-cap/23/09/34771681/hedge-fund-titan-peter-brown-built-a-large-language-model-35-years-ago-read-what-it-wrote">recent passing of Simons</a>. The fund continues to leverage complex mathematical models and algorithmic trading, an approach pioneered by Simons that has consistently outperformed traditional investment methods.
Renaissance&#8217;s Medallion Fund, renowned for its exceptional performance, has delivered annual returns of 62% (37% after fees) between 1988 and 2021. This track record has solidified Simons&#8217; legacy as <a href="https://www.benzinga.com/news/24/04/38431687/jim-simons-a-math-professor-became-one-of-the-most-successful-investors-of-all-time-now-he-shares-hi">one of the greatest investors of all time</a>, surpassing even Warren Buffett in terms of returns.
At the time of his death, Simons&#8217; <a href="https://www.benzinga.com/news/24/05/38768433/jim-simons-groundbreaking-quantitative-hedge-fund-founder-who-provided-exceptional-returns-for-inves">net worth was estimated</a> at $31.4 billion, according to Forbes. His legacy extends beyond finance, with significant philanthropic contributions to mathematics and science education. Notably, in 1964, Simons took a highly classified position at the Institute for Defense Analyses, supporting the NSA in cracking Soviet codes and ciphers.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40435655/warren-buffetts-189b-cash-pile-not-a-sign-of-looming-market-crash-says-fund-manager-everybody-gets-e">Warren Buffett&#8217;s $189B Cash Pile Not A Sign Of Looming Market Crash, Says Fund Manager: &#8216;Everybody Gets Excited&#8230; But It&#8217;s Not That Big Of A Number&#8217;</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editor

NSA Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings

U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Monday.
Shares of ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) rose sharply during Monday's session after the company reported better-than-expected second-quarter financial results and <a href="https://www.benzinga.com/news/earnings/24/08/40439449/why-is-israel-based-cargo-shipping-company-zim-integrated-stock-surging-today">raised its FY24 guidance.</a>
ZIM Integrated Shipping reported a second-quarter sales increase of 48% Y/Y to $1.93 billion, beating the consensus of $1.80 billion. The Haifa, Israel-based company generated an EPS of $3.08, vs a loss of $1.79 last year, beating the consensus of $1.66.
ZIM Integrated Shipping Services shares jumped 19.6% to $22.80 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>fuboTV Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) shares jumped 29% to $1.9700 after a judge temporarily blocked the Fox-Disney-Warner streaming venture, Venu.</li>
<li>Foghorn Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) gained 20.9% to $7.57. Evercore ISI Group analyst Gavin Clark-Gartner initiated coverage on Foghorn Therapeutics with an Outperform rating and announced a price target of $20.</li>
<li>Lyell Immunopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) rose 13.7% to $1.3879. HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterated Lyell Immunopharma with a Neutral and maintained a $1 price target.</li>
<li>Xperi Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPER#NYSE">XPER</a>) shares jumped 13.7% to $8.59 after the company announced that it entered into an agreement with Amazon.com services for the sale of nearly all assets and some liabilities for $80 million.</li>
<li>Inozyme Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) gained 12% to $5.13.</li>
<li>TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) rose 11.6% to $24.66.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) gained 11% to $34.47.</li>
<li>Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) shares climbed 10.7% to $8.27.</li>
<li>Inozyme Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) rose 10.7% to $5.07.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) gained 9.4% to $33.95.</li>
<li>Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) rose 8% to $3.940.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) surged 6.6% to $23.70.</li>
<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) surged 5.6% to $339.10.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) gained 5.2% to $167.50.</li>
<li>Amer Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) rose 5.5% to $12.09.</li>
<li>KB Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) gained 4.2% to $65.35.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40437035/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-delivering-high-dividend-y">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>

APPS

ASTS

FUBO

INZY

LYEL

TGTX

VALN

XPER

ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) shares dipped 18.18% after the company reported a <a href="https://www.benzinga.com//node/40333133" target="_blank" rel="noreferrer noopener">second-quarter revenue miss</a>. Several analysts cut <a href="https://www.benzinga.com//node/40333133" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) stock fell 5.92% last week. RBC Capital lowered its price target on the stock <a href="https://www.benzinga.com/quote/mbly/analyst-ratings" target="_blank" rel="noreferrer noopener">from $34 to $24</a>.</li>
<li>Rivian Automotive Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) stock declined 5.37% after it reportedly halted production of the electric commercial van it makes for Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) due to a parts deficit in the latest supply chain chaos.</li>
<li>Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) stock decreased 4.87% after the company announced that Chairman and CEO Brian Niccol <a href="https://www.benzinga.com//node/40376234" target="_blank" rel="noreferrer noopener">would be leaving.</a> Several analysts revised ratings and <a href="https://www.benzinga.com//node/40367589" target="_blank" rel="noreferrer noopener">price targets on the stock</a>.</li>
<li>Lineage Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) stock lost 4.08% in the last week.</li>
<li>Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) stock fell 3.85% last week after gaining earlier in the week on reports of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) increasing its stake in the company.</li>
<li>Hershey Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) stock lost 3.23% after Goldman Sachs issued a <a href="https://www.benzinga.com//node/40321537" target="_blank" rel="noreferrer noopener">Sell rating and</a> a price target of $185 on the stock.</li>
<li>Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) shares were down 2.80% after the company announced a <a href="https://www.benzinga.com//node/40342215">definitive agreement to divest</a> its Vantive Kidney Care segment to Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) for $3.8 billion.</li>
<li>Broadridge Financial Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) declined 2.76%.</li>
<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) shares decreased 2.38%.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40431642/nvidia-starbucks-and-dell-are-among-top-10-large-cap-gainers-last-week-aug-11-aug-17-are-the-other" target="_blank" rel="noreferrer noopener">NVIDIA, Starbucks And Dell Are Among Top 10 Large Cap Gainers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?</a></li>
</ul>
Photo courtesy Rivian

Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?

SNAP

VNOM

VSTS

Soros Fund Management Q2 2024 13F Shows Exited 1.36M Vestis Shares, 251.8K Freeport-McMoRan Shares, 30.6K Micron Shares, 1.4M Snap Shares, 313.85K Viper Energy Shares, 16.9K NextEra Energy Shares, 1.05K United Therapeutics Shares, And 50K 3M Shares

Rumors

Watching Liquidia; Traders Circulate Unconfirmed Analyst Comments Suggesting United Therapeutics Has Filed A Lawsuit Against The FDA's Action On Liqudia's Lung-disease Treatment Yutrepia In Both PAH And PH-ILD

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) has outperformed the market over the past 10 years by 3.51% on an annualized basis producing an average annual return of 13.83%. Currently, United Therapeutics has a market capitalization of $14.58 billion. 
Buying $100 In UTHR: If an investor had bought $100 of UTHR stock 10 years ago, it would be worth $369.78 today based on a price of $327.68 for UTHR at the time of writing.
<h3>United Therapeutics's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722884412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today

HC Wainwright &amp; Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and maintains $400 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $400 Price Target

The biotech industry's future appears bright due to advancements in biochemical and pharma technologies, AI integration, rising targeted treatments, and increased R&D spending driving breakthroughs. Therefore, it could be wise to invest in undervalued biotech stocks such as Harmony Biosciences Holdings (HRMY), United Therapeutics (UTHR), and BioMarin Pharmaceutical (BMRN). Read on... The biotech sector is thriving as it advances in commercializing therapies for rare and new diseases, addressing unmet medical needs. Driven by rising global demand for quality healthcare, targeted treatments, and advanced technology, the industry's growth positions it as a promising investment opportunity for those seeking value in the healthcare landscape.
Hence, investors could consider buying undervalued biotech stocks: Harmony Biosciences Holdings, Inc. (<a href="https://stocknews.com/stock/HRMY/">HRMY</a>), United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>), and BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>), which look ready for a breakout.
The biotech industry saw strong Q2 performance, driven by mergers and acquisitions, particularly in oncology and immunology. Major R&amp;D breakthroughs included GLP-1 drugs, CAR-T therapies, nuclear medicine, and neurological treatments. In addition, venture capital funding surged, especially in biopharma innovation. The global biotech market is projected to reach $3.88 trillion by 2030, growing at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">14% CAGR</a>.
Meanwhile, biotech is being revolutionized by AI innovations that optimize drug manufacturing, enhance protein structure analysis, and improve cancer detection through advanced blood tests, driving cost efficiency and scalability. Notably, the global AI market for pharma and biotech is projected to reach $4.20 billion by 2027, with a <a href="https://www.linkedin.com/pulse/ai-pharma-biotech-market-size-2024-growth-u229e/">CAGR of 30.5%</a>.
Furthermore, investors' interest in biotech stocks is evident from the SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 23.4% returns over the past nine months. Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Harmony Biosciences Holdings, Inc. (<a href="https://stocknews.com/stock/HRMY/">HRMY</a>)
HRMY is a commercial-stage pharmaceutical company that focuses on developing and commercializing therapies for patients with rare and other neurological diseases. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
On June 24, 2024, HRMY Biosciences announced FDA approval for WAKIX (pitolisant) tablets to treat excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy. WAKIX is now the first non-scheduled treatment for pediatric narcolepsy patients.
In terms of forward non-GAAP P/E, HRMY's 12.42x is 41.5% lower than the 21.23x industry average. Its 0.54x forward non-GAAP <a href="https://www.investopedia.com/terms/p/pegratio.asp">PEG</a> is 72.5% lower than the 1.98x industry average. Similarly, its 10.06x forward EV/EBITDA is 26.5% lower than the 13.68x industry average.
During the fiscal first quarter ended March 31, 2024, HRMY's net product revenue increased 28.8% year-over-year to $172.81 million. The company's gross profit of $140.67 million reflects a growth of 28.8% from the prior year's quarter. Likewise, its non-GAAP adjusted net income was $60.61 million, or $1.05 per share, up 32.1% and 38.2% year-over-year, respectively.
Analysts expect HRMY's revenue for the quarter ending September 30, 2024, to increase 15.2% year-over-year to $184.62 million. Its EPS for the same quarter is expected to grow 5.3% year-over-year to $0.66. The company surpassed the Street revenue estimates in each of the trailing four quarters. Over the past three months, the stock has gained 16.6%, closing the last trading session at $35.59.
HRMY's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its positive prospects. It has an overall B rating, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
HRMY has an A grade for Value and a B for Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #29 out of 337 stocks. <a href="https://stocknews.com/stock/HRMY/">Click here</a> for the additional POWR Ratings of HRMY (Growth, Momentum, Stability, and Sentiment).
Stock #2: United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>)
UTHR is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally.
In terms of forward EV/EBIT, UTHR's 8.25x is 51.3% lower than the 16.93x industry average. Likewise, its 13.32x forward non-GAAP P/E is 37.3% lower than the 21.23x industry average. Also, its 0.96x forward non-GAAP PEG is 51.7% lower than the 1.98x industry average.
UTHR's total revenues for the second quarter, which ended June 30, 2024, increased 19.8% year-over-year to $714.90 million. Its operating income rose 2.1% from the year-ago value to $319.90 million. For the same quarter, the company's net income came in at $278.10 million, or $5.85 per common share, representing an increase of 7.3% and 11.6% over the prior-year quarter, respectively.
Street expects UTHR's EPS and revenue for the quarter ending September 30, 2024, is expected to increase 20.8% and 19.3% year-over-year to $6.50 and $726.96 million, respectively. It surpassed the consensus EPS estimates in three of the trailing four quarters. UTHR's stock has gained 57.5% year-to-date to close the last trading session at $346.32.
UTHR's positive outlook is reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
It has an A grade for Value and a B for Quality. Within the same industry, it is ranked #22. Beyond what we stated above, we also have given UTHR grades for Growth, Momentum, Stability, and Sentiment. Get all the UTHR ratings <a href="https://stocknews.com/stock/UTHR/">here</a>.
Stock #1: BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>)
BMRN develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, Naglazyme, and Kuvan.
On July 24, 2024, BMRN announced that the U.S. FDA approved BRINEURA (cerliponase alfa) for children under 3 years with CLN2 disease. The approval expands the treatment to all ages, including presymptomatic children, to slow the loss of ambulation.
In terms of forward non-GAAP PEG, BMRN's 0.95x is 52.2% lower than the 1.98x industry average.
For the fiscal second quarter (ended June 30, 2024), BMRN's total revenues increased 19.6% year-over-year to $712 million. Its non-GAAP net income and non-GAAP EPS rose 79.6% and 77.8% over the prior-year quarter to $188.90 million and $0.96, respectively.
Moreover, BMRN's total cash, cash equivalents, and investments as of June 30, 2024, stood at $1.78 billion compared to $1.68 billion as of December 31, 2023.
For the quarter ending September 30, 2024, BMRN's EPS and revenue are expected to increase 74% and 21.1% year-over-year to $0.80 and $704.18 million, respectively. BMRN surpassed the EPS estimates in three of the trailing four quarters. Over the past three months, the stock has gained 3.9% to close the last trading session at $83.96.
It's no surprise that BMRN has an overall rating of B, which translates to a Buy in our proprietary rating system.
It is ranked #15 in the Biotech industry. It has an A grade for Growth and a B for Value, and Sentiment. <a href="https://stocknews.com/stock/BMRN/">Click here</a> to see BMRN's Momentum, Stability, and Quality ratings.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
BMRN shares were trading at $83.67 per share on Monday afternoon, down $0.41 (-0.49%). Year-to-date, BMRN has declined -13.22%, versus a 15.35% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/bmrn-uthr-hrmy-undervalued-biotech-stocks-ready-for-a-breakout/>Undervalued Biotech Stocks Ready for a Breakout</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Undervalued Biotech Stocks Ready for a Breakout

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Stocks with low P/E ratios can offer great returns as the market catches on to their true potential. In this article, we discuss three undervalued picks Kroger (KR), Textron (TXT), and United Therapeutics (UTHR), with P/E ratios below 15. Keep reading… Everyone loves getting a good deal, whether it's a discount on groceries, a two-for-one sale, or a great price on a car. When it comes to value stocks, however, the real benefit comes when the market recognizes the stock's true value and its price increases.
Stocks with low <a href="https://www.investopedia.com/terms/p/price-earningsratio.asp">price-to-earnings (P/E)</a> ratios are especially appealing for long-term investors. As these stocks' valuations increase over time, they often provide attractive returns. Below, I have highlighted three such undervalued stocks that are trading at P/E ratios under 15, namely, The Kroger Co. (<a href="https://stocknews.com/stock/KR/">KR</a>), Textron Inc. (<a href="https://stocknews.com/stock/TXT/">TXT</a>), and United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>).
But first, let's understand what a P/E ratio is.
The P/E ratio compares a company's stock price to its earnings per share (EPS), helping investors gauge how much they pay for every dollar of earnings. It's calculated by dividing the stock price by the company's earnings per share and can be based on trailing (past) or forward (future) earnings projections.
Factors such as interest rates, expected growth, and market sentiment influence a company's P/E ratio. A low P/E ratio could signal a short-term challenge, but it doesn't necessarily mean the company isn't growing. Many investors have profited by investing in undervalued stocks that the market temporarily overlooked. Once these companies outperform expectations, their earnings and stock prices rise.
However, relying solely on P/E ratios without considering a company's growth and fundamentals could be risky. So, let's explore the fundamental aspects of KR, TXT, and UTHR to understand their potential in detail:
The Kroger Co. (<a href="https://stocknews.com/stock/KR/">KR</a>)
KR is a food retailer that owns and operates combination food and drug stores, supermarkets, multi-department stores, and price-impact warehouses. It offers grocery, health, and beauty care items, general merchandise (including apparel, home goods, and toys), pet centers, fresh seafood, and organic produce.
On June 27, KR increased its dividend by 10.3% from $1.16 to $1.28 per share annually, marking the 18th consecutive year of dividend increases. The quarterly dividend of 29 cents per share was paid to its shareholders on September 1, 2023.
KR's annual dividend yields 2.46% at the current price level, while its four-year average yield is 2.01%. Its dividend payouts have increased at a 16.6% CAGR over the past three years and a 15.5% CAGR over the past five years.
In terms of forward non-GAAP P/E, KR is trading at 11.71x, 35.7% lower than the industry average of 18.21x. Likewise, the stock's forward EV/Sales and Price/Sales multiples of 0.36 and 0.25 are 79.2% and 80.8% below their respective industry averages of 1.74 and 1.31.
KR's sales increased marginally year-over-year to $45.27 billion in the first quarter that ended May 25, 2024, while its operating profit amounted to $1.29 billion. The company's adjusted net earnings for the period came in at $1.05 billion and $1.43 per share. As of May 25, 2024, KR's cash amounted to $345 million, representing an increase of 43.2% year-over-year.
Looking ahead to 2024, Kroger remains cautiously optimistic, with identical sales without fuel anticipated to grow between 0.25% and 1.75%. Adjusted FIFO operating profit is projected to be between $4.6 billion and $4.8 billion, while adjusted net earnings per diluted share are expected to range from $4.30 to $4.50.
Street expects KR's revenue for the quarter ending October 2024 to increase marginally year-over-year to $34.32 billion. Its EPS for the current quarter is expected to grow 3.6% year-over-year to $0.98. Also, KR surpassed the consensus EPS estimate in each of the trailing four quarters.
Over the past nine months, the stock has gained 14% to close the last trading session at $51.97.
KR's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this promising outlook. The stock's overall A rating translates to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has a B grade for Value, Sentiment, and Quality. Within the A-rated <a href="https://stocknews.com/category/grocery-big-box-retailers/">Grocery/Big Box Retailers</a> industry, it is ranked #8 out of 37 stocks.
To see the additional POWR Ratings of KR for Growth, Momentum, and Stability, <a href="https://stocknews.com/stock/KR/">click here</a>.
Textron Inc. (<a href="https://stocknews.com/stock/TXT/">TXT</a>)
TXT is a multi-industry company that leverages its global network of aircraft, defense, industrial, and finance businesses to provide customers with various solutions and services. It operates through six segments: Textron Aviation; Bell; Textron Systems; Industrial; Textron eAviation; and Finance. 
On August 21, Bell Textron Inc. (a TXT company) delivered a Bell 429 and a signed purchase agreement for two Bell 407GXi aircraft with the Chicago Police Department. Bell's advanced technology and multi-mission capabilities make these models ideal for public safety agencies. This continued partnership, lasting over 20 years, underscores Bell's leadership in the sector and highlights TXT's sustained influence and growth in the public safety aviation market.
In terms of forward non-GAAP P/E, TXT is trading at 13.77x, 27.1% lower than the industry average of 18.89x. The stock's forward EV/Sales of 1.30x is 26.5% lower than the industry average of 1.77x. Also, its forward Price/Sales multiple of 1.12 compares with the 1.40 industry average.
For the six months ended June 29, 2024, TXT's total revenues increased 3.3% year-over-year to $6.66 billion, while its segment profit improved by 3.6% from the year-ago value to $633 million. The company's adjusted income from continuing operations amounted to $529 million or $2.74 per share, representing an increase of 2.9% and 9.2% from last year, respectively.
According to the outlook for 2024, TXT forecasts adjusted income from continuing operations to range from $1.18 billion to $1.22 billion. The company also expects non-GAAP EPS to be between $6.20 and $6.40 and the manufacturing cash flow before pension contributions (non-GAAP) to range between $900 million and $1 billion.
Analysts expect TXT's revenues for the third quarter (ending September 2024) to increase 8.4% year-over-year to $3.62 billion, while its EPS for the same period is expected to grow 6.4% from the prior year to $1.58. Moreover, the company has surpassed the consensus EPS estimates in three of the trailing four quarters, which is promising.
The stock has gained 14.4% over the past nine months to close the last trading session at $86.88.
TXT's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Value and a B for Momentum and Quality. It is ranked #4 out of 71 stocks in the <a href="https://stocknews.com/category/air-defense/">Air/Defense Services</a> industry. <a href="https://stocknews.com/stock/TXT/">Click here</a> to see TXT's ratings for Growth, Stability, and Sentiment.
United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>)
UTHR, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
In terms of forward non-GAAP P/E, UTHR is trading at 13.44x, which is 36.7% lower than the industry average of 21.23x. The stock's forward EV/EBITDA of 8.07x is 41.2% lower than the industry average of 13.73x. Also, its forward EV/EBIT multiple of 8.34 is 50.8% below the industry average of 16.97x.
UTHR's revenues increased 19.8% year-over-year to $714.90 million in the fiscal second quarter ended June 30, 2024. Its operating income grew 2.1% year-over-year to $319.90 million over the period, while its net income and net income per share increased 7.3% and 11.6% from its year-ago values to $278.10 million and $5.85, respectively.
The consensus EPS estimate of $6.50 for the fiscal third quarter (ending September 2024) represents a 20.8% improvement year-over-year. The consensus revenue estimate of $726.96 million for the ongoing quarter represents a 19.3% increase from last year. The company has an excellent surprise history; it surpassed the consensus revenue estimates in each of the trailing four quarters.
Shares of UTHR have gained 43.5% over the past six months and 58.6% year-to-date to close the last trading session at $348.71.
It is no surprise that UTHR has an overall rating of B, which equates to a Buy in our POWR Ratings system. It has an A grade for Value and a B for Quality. Also, it is ranked #23 among 337 stocks in the<a href="https://stocknews.com/category/biotech/"> Biotech</a> industry.
In addition to the POWR Rating grades I've just highlighted, you can see UTHR's Growth, Momentum, Stability, and Sentiment ratings <a href="https://stocknews.com/stock/UTHR/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>
&nbsp;
<hr />
KR shares were trading at $52.22 per share on Tuesday afternoon, up $0.25 (+0.48%). Year-to-date, KR has gained 16.29%, versus a 15.34% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/kr-txt-uthr-3-value-stocks-to-buy-with-p-e-ratios-below-15/>3 Value Stocks to Buy with P/E Ratios Below 15</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Value Stocks to Buy with P/E Ratios Below 15

BlackRock Health Sciences Term Trust Q2 2024 Commentary

Janus Henderson Global Life Sciences Fund Q2 2024 Commentary

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease.

U.S. Stock: United Therapeutics Corp

'Buy this; sell that' within each sector – Oppenheimer

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

JMEE: Actively Managed ETF In Line With Its Objective

ABBV

AGCO

ALNY

AMGN

APLE

ASND

AVDL

AVNT

AZNCF

BHVN

BMEZ

BOOT

BWXT

CABA

CACI

CARG

CARS

COHR

CWEN

ETNB

EXEL

FDMT

GMED

GOSS

HRMY

IMCR

INSM

ISRG

JACK

JHMM

JMEE

KROS

LAMR

MDYG

MDYV

MNKD

MRUS

NGNE

NONOF

NVSEF

PRGO

PSTG

RHHBF

RHHBY

RHHVF

SARTF

SILK

SITM

SMPL

SNYNF

SOAGY

SRPT

SSSGY

SUVPF

TSHA

XMMO

Press Releases

United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer

United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors

FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment

United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024

United Therapeutics Corporation Reports Second Quarter 2024 Financial Results

United Therapeutics Corporation to Present at Upcoming Investor Conferences

United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

Comments

United Therapeutics

뉴스

에 대한 최신 뉴스 United Therapeutics (NASDAQ:UTHR) 주식

화요일, 8월 20, 2024

일요일, 8월 18, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌